Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.63 |
| ▸ | ADORA1 | P30542 | 14/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.54 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2328134 | 0.84 | ADORA1 (0.59) | KDM4EALDH1A1ADORA2AADORA1ADORA2B | |
| SCHEMBL7542561 | 0.83 | ADORA2A (0.55) | KDM4ELMNAALDH1A1GAAADORA2A | |
| SCHEMBL27881848 | 0.81 | ADORA2A (0.57) | KDM4ELMNAALDH1A1GAAADORA2A | |
| SCHEMBL27881822 | 0.80 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL27881814 | 0.80 | ADORA2A (0.65) | KDM4ELMNAALDH1A1GAAADORA2A | |
| SCHEMBL27899092 | 0.79 | ADORA2A (0.54) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL30186658 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL2324215 | 0.78 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BCSNK1A1CLK4 | |
| SCHEMBL27899286 | 0.77 | ADORA2A (0.54) | KDM4EALDH1A1GAAADORA2AADORA1 | |
| SCHEMBL2327082 | 0.77 | ADORA2A (0.76) | ALDH1A1ADORA2AADORA1ADORA2BCSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102822150-A | 1,2, 4-triazin-4-amine derivatives | HEPTARES THERAPEUTICS LTD | 2012-12-12 | — | — | CN | claimed |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | NXERA PHARMA UK LIMITED (GB) | 2024-08-06 | — | — | US | disclosed |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-27 | — | — | US | disclosed |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2019-02-14 | — | — | US | disclosed |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2017-10-12 | — | — | US | disclosed |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-06-23 | — | — | US | disclosed |
| EP-2531492-B1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LTD (GB) | 2016-04-13 | — | — | EP | disclosed |
| US-9249130-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | NXERA PHARMA UK LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| CN-102822150-B | 1,2, 4-triazin-4-amine derivatives | HEPTARES THERAPEUTICS LTD | 2014-12-03 | — | — | CN | disclosed |
| US-8809525-B2 | 1,2,4-triazine-4-amine derivatives | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-08-19 | — | — | US | disclosed |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2013-01-31 | — | — | US | disclosed |
| EP-2531492-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | Heptares Therapeutics Limited (GB) | 2012-12-12 | — | — | EP | disclosed |
| CN-102822150-A | 1,2, 4-triazin-4-amine derivatives | HEPTARES THERAPEUTICS LTD | 2012-12-12 | — | — | CN | disclosed |
| WO-2011095625-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | HEPTARES THERAPEUTICS LIMITED (GB) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005276-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | KDM4E 3814/4885LMNA 1324/4885ALDH1A1 784/4885 |
| US-20190047978-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | KDM4E 3814/4885LMNA 1324/4885ALDH1A1 784/4885 |
| US-10988455-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | KDM4E 3814/4885LMNA 1324/4885ALDH1A1 784/4885 |
| US-20160175314-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | KDM4E 3851/4885LMNA 1268/4885ALDH1A1 794/4885 |
| US-20230021177-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | KDM4E 4021/4885LMNA 1300/4885ALDH1A1 788/4885 |
| US-10112923-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2B, ADORA2A, ADORA1 | KDM4E 3847/4885LMNA 1387/4885ALDH1A1 763/4885 |
| US-12054472-B2 | 1,2,4-triazine-4-amine derivatives | ADORA2A, ADORA2B, ADORA1 | KDM4E 3861/4885LMNA 1724/4885ALDH1A1 251/4885 |
| US-20170291888-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | PTGER1, LTB4R2, LTB4R | KDM4E 3792/4885LMNA 1381/4885ALDH1A1 1211/4885 |
| US-20130029963-A1 | 1,2,4-TRIAZINE-4-AMINE DERIVATIVES | ADORA2B, ADORA2A, ADORA1 | KDM4E 3814/4885LMNA 1324/4885ALDH1A1 784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.